Q9988 Platelets (HCPCS) Reimbursement & Policy

HCPCS Level II code Q9988 denotes apheresis-derived platelet units that have undergone pathogen-reduction processing. These units are used in transfusion for patients with thrombocytopenia or platelet dysfunction when reduced infectious risk is desired. Nationally, pathogen-reduced platelet products are an evolving clinical and billing area because they carry higher preparation costs but may reduce transfusion-related infectious complications and simplify certain screening or irradiation requirements.

Key payers covered include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of what Q9988 represents, payer coverage patterns and benchmarks, typical billing scenarios and sites of service, and relevant policy updates affecting reimbursement for pathogen-reduced blood products. The publication summarizes clinical context for use of pathogen-reduced platelets, highlights common coding and billing considerations, and points to related codes and documentation elements where available.

Data not available in the input for specific modifiers, taxonomies, ICD-10 pairings, and detailed payer policy language are noted where applicable. The focus is national in scope and intended for revenue cycle, transfusion service, and policy audiences seeking a clear summary of HCPCS Level II code Q9988 and its implications.

Billing Code Overview

HCPCS Level II code Q9988 describes platelets, pheresis, pathogen-reduced, each unit. This code represents a blood product unit prepared by apheresis and treated with a pathogen-reduction process to decrease the risk of transfusion-transmitted infections.

Service type: Therapeutic and transfusion blood product (platelet unit preparation)
Typical site of service: Hospital outpatient transfusion service, inpatient hospital blood bank, or specialized transfusion center

Clinical Context

A typical patient is an adult admitted for hematologic support due to thrombocytopenia from chemotherapy, aplastic anemia, or immune thrombocytopenic purpura who requires transfusion of apheresis platelets that have undergone pathogen-reduction processing. The clinical workflow begins with the treating hematologist or transfusion medicine physician ordering platelet transfusion specifying pathogen-reduced apheresis platelets. Pretransfusion testing includes verification of patient identity, blood type, and any necessary antibody screens. The transfusion service retrieves a unit labeled as Q9988 (platelets, pheresis, pathogen-reduced, each unit), confirms product compatibility and pathogen-reduction labeling, and prepares the unit per institutional transfusion protocols. Nursing performs baseline vital signs, monitors for transfusion reactions during and after the infusion, and documents volume infused and unit identifiers. Post-transfusion assessment includes platelet count monitoring to determine efficacy and need for additional units. Typical sites of service are hospital inpatient units, outpatient infusion centers, specialty transfusion clinics, and ambulatory oncology centers where transfusion support is provided.

Coding Specifications

Modifier	Description	When to Use
`59`	Distinct procedural service	When an unrelated transfusion procedure or separate vascular access service is performed on the same day and must be reported separately

Taxonomy Code	Specialty	Notes
`207RH0000X`	Hematology & Oncology	Ordering physicians who manage thrombocytopenia and transfusion needs
`207RR0500X`	Transfusion Medicine	Specialists overseeing blood product selection and safety
`207L00000X`	Pathology	Pathologists involved in blood bank oversight and product qualification
`251B00000X`	Registered Nursing	Nurses who administer and monitor transfusions in inpatient and outpatient settings
`208D00000X`	Internal Medicine	Hospitalists who coordinate inpatient transfusion orders and care

Related Diagnoses

ICD-10 Code	Description	Clinical Relevance
`D69.6`	Thrombocytopenia, unspecified	Common indication for platelet transfusion when platelet counts are low or bleeding risk is high
`D61.9`	Aplastic anemia, unspecified	Patients with marrow failure often require platelet support with apheresis platelets
`C91.10`	Chronic myelogenous leukemia, BCR/ABL-positive, in remission	Patients receiving chemotherapy for hematologic malignancies can develop thrombocytopenia necessitating platelet transfusion
`C90.00`	Multiple myeloma not having achieved remission	Chemotherapy-induced thrombocytopenia in oncology patients commonly requires platelet support
`D69.3`	Immune thrombocytopenic purpura	Autoimmune platelet destruction can require therapeutic platelet transfusion in severe bleeding

Related CPT Codes

CPT Code	Description	Relationship to This Procedure
`36430`	Transfusion or infusion of blood product (separate procedure code indicating transfusion)	Used to report the administration of blood products such as platelets in the clinical setting alongside the product billing code
`86830`	Compatibility studies, blood, whole blood or red blood cells, antibody screen	Performed prior to transfusion to assess for clinically significant antibodies that may impact product selection
`36416`	Collection of venous blood by venipuncture	Often performed for pretransfusion testing such as type and screen or crossmatch
`99000`	Handling and/or conveyance of specimen for transfer from physician office to another lab	Applicable when specimens for transfusion testing are sent externally
`99070`	Supplies and materials (e.g., sterile water, bandages) used during patient care not included in other codes	May be used by some payers for non-covered supply charges related to transfusion administration

OpenPayer

Summary & Overview

HCPCS Q9988: Platelets, Pheresis, Pathogen-Reduced, Each Unit